Literature DB >> 18349139

Differential interactions of thin filament proteins in two cardiac troponin T mouse models of hypertrophic and dilated cardiomyopathies.

Raffaella Lombardi1, Achim Bell, Vinitha Senthil, Jasvinder Sidhu, Michela Noseda, Robert Roberts, Ali J Marian.   

Abstract

AIM: Mutations in a sarcomeric protein can cause hypertrophic cardiomyopathy (HCM) or dilated cardiomyopathy (DCM), the opposite ends of a spectrum of phenotypic responses of the heart to mutations. We posit the contracting phenotypes could result from differential effects of the mutant proteins on interactions among the sarcomeric proteins. To test the hypothesis, we generated transgenic mice expressing either cardiac troponin T (cTnT)-Q92 or cTnT-W141, known to cause HCM and DCM, respectively, in the heart. METHODS AND
RESULTS: We phenotyped the mice by echocardiography, histology and immunoblotting, and real-time polymerase chain reaction. We detected interactions between the sarcomeric proteins by co-immunoprecipitation and determined Ca2+ sensitivity of myofibrillar protein ATPase activity by Carter assay. The cTnT-W141 mice exhibited dilated hearts and decreased systolic function. In contrast, the cTnT-Q92 mice showed smaller ventricles and enhanced systolic function. Levels of cardiac troponin I, cardiac alpha-actin, alpha-tropomyosin, and cardiac troponin C co-immunoprecipitated with anti-cTnT antibodies were higher in the cTnT-W141 than in the cTnT-Q92 mice, as were levels of alpha-tropomyosin co-immunoprecipitated with an anti-cardiac alpha-actin antibody. In contrast, levels of cardiac troponin I co-immunoprecipitated with an anti-cardiac alpha-actin antibody were higher in the cTnT-Q92 mice. Ca2+ sensitivity of myofibrillar ATPase activity was increased in HCM but decreased in DCM mice compared with non-transgenic mice.
CONCLUSION: Differential interactions among the sarcomeric proteins containing cTnT-Q92 or cTnT-W141 are responsible for the contrasting phenotypes of HCM or DCM, respectively.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18349139      PMCID: PMC2773799          DOI: 10.1093/cvr/cvn078

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  28 in total

Review 1.  Molecular mechanisms of cardiac myofilament activation: modulation by pH and a troponin T mutant R92Q.

Authors:  R John Solaro; Jamie Varghese; A J Marian; Murali Chandra
Journal:  Basic Res Cardiol       Date:  2002       Impact factor: 17.165

2.  A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation.

Authors:  A A Geisterfer-Lowrance; S Kass; G Tanigawa; H P Vosberg; W McKenna; C E Seidman; J G Seidman
Journal:  Cell       Date:  1990-09-07       Impact factor: 41.582

3.  The purification of cardiac myofibrils with Triton X-100.

Authors:  R J Solaro; D C Pang; F N Briggs
Journal:  Biochim Biophys Acta       Date:  1971-08-06

4.  Novel cardiac troponin T mutation as a cause of familial dilated cardiomyopathy.

Authors:  D Li; G Z Czernuszewicz; O Gonzalez; T Tapscott; A Karibe; J B Durand; R Brugada; R Hill; J M Gregoritch; J L Anderson; M Quiñones; L L Bachinski; R Roberts
Journal:  Circulation       Date:  2001-10-30       Impact factor: 29.690

5.  Cardiac troponin T mutation R141W found in dilated cardiomyopathy stabilizes the troponin T-tropomyosin interaction and causes a Ca2+ desensitization.

Authors:  Qun-Wei Lu; Sachio Morimoto; Keita Harada; Cheng-Kun Du; Fumi Takahashi-Yanaga; Yoshikazu Miwa; Toshiyuki Sasaguri; Iwao Ohtsuki
Journal:  J Mol Cell Cardiol       Date:  2003-12       Impact factor: 5.000

6.  Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere.

Authors:  L Thierfelder; H Watkins; C MacRae; R Lamas; W McKenna; H P Vosberg; J G Seidman; C E Seidman
Journal:  Cell       Date:  1994-06-03       Impact factor: 41.582

7.  Evolution of expression of cardiac phenotypes over a 4-year period in the beta-myosin heavy chain-Q403 transgenic rabbit model of human hypertrophic cardiomyopathy.

Authors:  Sherif F Nagueh; Suetnee Chen; Rajnikant Patel; Natalia Tsybouleva; Silvia Lutucuta; Helen A Kopelen; William A Zoghbi; Miguel A Quiñones; Robert Roberts; A J Marian
Journal:  J Mol Cell Cardiol       Date:  2004-05       Impact factor: 5.000

8.  Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy.

Authors:  Natalia Tsybouleva; Lianfeng Zhang; Suetnee Chen; Rajnikant Patel; Silvia Lutucuta; Shintaro Nemoto; Gilberto DeFreitas; Mark Entman; Blase A Carabello; Robert Roberts; A J Marian
Journal:  Circulation       Date:  2004-03-01       Impact factor: 29.690

9.  Transgenic analysis of the thyroid-responsive elements in the alpha-cardiac myosin heavy chain gene promoter.

Authors:  A Subramaniam; J Gulick; J Neumann; S Knotts; J Robbins
Journal:  J Biol Chem       Date:  1993-02-25       Impact factor: 5.157

10.  Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy.

Authors:  H Watkins; W J McKenna; L Thierfelder; H J Suk; R Anan; A O'Donoghue; P Spirito; A Matsumori; C S Moravec; J G Seidman
Journal:  N Engl J Med       Date:  1995-04-20       Impact factor: 91.245

View more
  34 in total

Review 1.  Hypertrophic cardiomyopathy: from genetics to treatment.

Authors:  Ali J Marian
Journal:  Eur J Clin Invest       Date:  2010-04       Impact factor: 4.686

2.  Modeling human disease phenotype in model organisms: "It's only a model!".

Authors:  Ali J Marian
Journal:  Circ Res       Date:  2011-08-05       Impact factor: 17.367

Review 3.  Research priorities in sarcomeric cardiomyopathies.

Authors:  Jolanda van der Velden; Carolyn Y Ho; Jil C Tardiff; Iacopo Olivotto; Bjorn C Knollmann; Lucie Carrier
Journal:  Cardiovasc Res       Date:  2015-01-28       Impact factor: 10.787

Review 4.  Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy.

Authors:  Ali J Marian; Eugene Braunwald
Journal:  Circ Res       Date:  2017-09-15       Impact factor: 17.367

Review 5.  Genetics and Genomics of Single-Gene Cardiovascular Diseases: Common Hereditary Cardiomyopathies as Prototypes of Single-Gene Disorders.

Authors:  Ali J Marian; Eva van Rooij; Robert Roberts
Journal:  J Am Coll Cardiol       Date:  2016-12-27       Impact factor: 24.094

6.  The functional effect of dilated cardiomyopathy mutation (R144W) in mouse cardiac troponin T is differently affected by α- and β-myosin heavy chain isoforms.

Authors:  Sampath K Gollapudi; Jil C Tardiff; Murali Chandra
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-02-13       Impact factor: 4.733

7.  Suppression of Activated FOXO Transcription Factors in the Heart Prolongs Survival in a Mouse Model of Laminopathies.

Authors:  Gaelle Auguste; Priyatansh Gurha; Raffaella Lombardi; Cristian Coarfa; James T Willerson; Ali J Marian
Journal:  Circ Res       Date:  2018-01-09       Impact factor: 17.367

8.  Human molecular genetic and functional studies identify TRIM63, encoding Muscle RING Finger Protein 1, as a novel gene for human hypertrophic cardiomyopathy.

Authors:  Suet Nee Chen; Grazyna Czernuszewicz; Yanli Tan; Raffaella Lombardi; Jianping Jin; James T Willerson; Ali J Marian
Journal:  Circ Res       Date:  2012-07-19       Impact factor: 17.367

9.  Genetic fate mapping identifies second heart field progenitor cells as a source of adipocytes in arrhythmogenic right ventricular cardiomyopathy.

Authors:  Raffaella Lombardi; Jinjiang Dong; Gabriela Rodriguez; Achim Bell; Tack Ki Leung; Robert J Schwartz; James T Willerson; Ramon Brugada; Ali J Marian
Journal:  Circ Res       Date:  2009-04-09       Impact factor: 17.367

10.  Pathogenesis of hypertrophic cardiomyopathy caused by myozenin 2 mutations is independent of calcineurin activity.

Authors:  Alessandra Ruggiero; Suet Nee Chen; Raffaella Lombardi; Gabriela Rodriguez; Ali J Marian
Journal:  Cardiovasc Res       Date:  2012-09-17       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.